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ABSTRACT 
The present prospective study was designed to conduct a local survey on patients under 
anti-tuberculosis therapy hospitalized in Abo-Seta hospital, Tripoli, Libya from the safety point 
of view. The study was carried out on 75 inpatients. The effects of the used drugs on some 
hematological parameters and liver function biomarkers were monitored for six-month period of 
treatment. Our survey showed that tuberculosis affects people with low and medium levels of 
education and with no job. The frequency of adverse effects related to treatment with Abo-Seta 
hospital regimen were decreases in WBCs count (-38.7%), RBCs count (-32.1%), platelets count 
(-33%)  and  hemoglobin  concentration  (-35.5%).  However,  in  most  of  the  cases,  it  was  not 
necessary  to  modify  the  treatment  regimen  because  of  such  side  effects.  Some  parameters 
showed  spontaneous  recovery  as  RBCs  count  (+22.1%)  and  hemoglobin  level  (+20.1%). 
Combined therapy of ethambutol, isoniazid, pyrazinamide, and rifampicin has been used in Abo-
Seta hospital, as a regimen for tuberculosis infection, may be associated with a high risk of 
hepatic toxicity during first month of treatment. However, during the remaining five months 
there was a good recovery of liver enzymes profile. Upon the data obtained from the present 
study, it could be concluded that TB patient after 6 month of treatment didn't develop multi-drug 
resistant tuberculosis (MDR-TB) 
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INTRODUCTION 
Tuberculosis  (TB)  is  one  of  the 
most common infectious diseases caused by 
Mycobacterium  tuberculosis  (M. 
tuberculosis)  (1).  Tuberculosis  is  still  a 
major  cause  of  death  from  an  infectious 
agent  in  developing  countries,  and 
constitutes a serious threat in large cities of 
industrialized  countries  (2).  Environmental 
characteristics such as crowding and social 
factors had a large  impact  on  exposure to 
the disease (3). In 1990, approximately, 1.7 
billion  humans  were  estimated  to  be 
infected worldwide (about one-third of the 
world's  population)  (4).  Tuberculosis  has 
reemerged  as  an  important  public  health 
problem  in  past  as  well  at  recent  time  in 
Libya.  At  2008  about  1000 TB  cases  had 
been  reported  (5).  Also,  in  Libya,  there 
were a few studies on such serious problem; 
one  of these studies shows the  number  of 
Libyan patients whom tuberculosis has been 
bacteriological confirmed (6), table 1. 
 
Table (1): Numbers of Libyan confirmed TB 
cases during 1990-2009 (6). 
Year  1990  1996  1999  2003  2005  2009 
Incidence 
of TB / 
100.000 
41  40  23  20  18  16 
 
M. tuberculosis was first isolated in 
1882 by the German physician Robert Koch 
who  received  the  Nobel  Prize  for  this 
discovery. TB spreads  most commonly by 
airborne  transmission  and  can  affect  any 
part of the body but  most  often the  lungs 
(5). TB, which occurs scattered throughout 
the body, is referred to as miliary TB. Extra-
pulmonary  TB  is  more  common  in 
immunodeficiency  persons  and  in  young  
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children  (7).  The  classic  symptoms  of  TB 
are  a  chronic  cough  with  blood-tinged 
sputum,  fever,  night  sweats,  and  weight 
loss. Infection of other organs causes a wide 
range of symptoms. Only 5% of people who 
are  infected  but  not  sick  have  latent  TB 
infection. Those who have a latent infection 
are a symptomatic and do not feel sick. The 
diagnosis relies on radiology (chest X-Ray), 
tuberculin skin test, blood tests, as well as 
microscopic  examination  and 
microbiological culture of body fluids (8). 
If not treated TB properly, it can be 
fatal  (9).  Today,  persons  with  pulmonary 
TB  can  be  cured  with  different  types  of 
regimens  of  antibiotics.  One  of  these 
regimen  followed  by  the  Libyan  National 
Center for Disease Control (NCDC), which 
is  proposed  by  WHO  as  direct  observed 
therapy  for  short  period  (DOTS).  The 
protocol of this regimen is a 6-month course 
of  antibiotics  that  includes  isoniazid, 
rifampin,  pyrazinamide,  and  ethambutol 
during  the  first  2  months.  For  our 
knowledge  a  combination  of  drugs  may 
develop side effects on the body organs and 
the most related organ is liver, which is the 
metabolizing  organ  for  all  the  received 
drugs. These side effects may differ from a 
patient to another due to the behavioral and 
cultural  factors.  Moreover,  extensively 
drug-resistant  tuberculosis  is  an  emerging 
health  problem  that  threatens  TB  control 
worldwide, since a perfect treatment for this 
disease has not yet been found. 
In  Libya,  there  is  a  huge  gap 
between  researches  on  anti-tuberculosis 
drugs  and  their  effects  on  body  functions 
during  treatment  period.  Therefore,  we 
designed  this  study  to  conduct  a  local 
survey  on  patients  under  anti-tuberculosis 
therapy  hospitalized  in  Abo-Seta  hospital, 
Tripoli, Libya from the safety point of view. 
The  effects  of  the  used  drugs  on  the 
hematological parameters and liver function 
biomarkers  are  monitored  for  six-month 
period of treatment. 
 
SUBJECTS AND METHODS 
Subjects: 
Seventy-five  patients  were 
inpatients, in 2009, in Abo-Seta hospital, in 
the west north of Libya, diagnosed as newly 
infected by TB. All patients were diagnosed 
as pulmonary tuberculosis by chest X-Ray, 
medical history and sputum analysis. Some 
patients  had  normal  liver  function  while 
others  had  abnormal  due  to  positive 
hepatitis. Prior-therapy samples were taken 
as controls.  
Clinical monitoring: 
Complete  history  background  was 
taken  from  all  patients  via  questionnaires 
involving  name,  sex,  nationality, 
occupation,  social  status,  smoking, 
residence,  education,  number  of  family 
members,  number  of  rooms,  previous 
treatment, first symptoms, fever, sweating, 
chest  pain,  weakness,  anorexia,  weight, 
other diseases and any other information, if 
any.  Directly  observed  treatment  (DOT) 
were  also  recorded  according  to  CDC 
(2000) (8). 
Methods of treatment: 
Patients  received  the  following 
therapeutic regimen: isoniazid 50 mg once a 
day,  rifampicin  10  mg  once  a  day, 
pyrazinamide 25 mg once a day, ethambutol 
15 mg once a day and/or streptomycin 0.75 
g once a day. All patients were treated for 6 
months. 
Laboratory monitoring: 
1.  Monitoring  of  hematological 
parameters: 
Complete blood count (CBC) with 
more emphases regarding the effects on red 
blood cells (RBCs) count, white blood cells 
(WBCs) count were been determined using 
an  automated  hematology  Sysmex  (KS-
21N;  Sysmex  corporation,  (Kobe,  Japan)), 
in  Libyan  National  Center  for  Infectious 
Disease  Prevention  and  Control  (NCDC). 
Anti-HIV,  anti-HBV,  anti-HCV  antibodies 
were  detected by ELISA. For CBC, blood 
samples  of  5  ml  were  collected  in  special 
heparinized tubes to prevent clotting of the 
samples;  additional  10  ml  were  collected 
without anticoagulant for detection for HIV, 
HBV and HBV antibodies. 
2. Monitoring of the drug effect on liver 
functional parameters: 
Patients’  liver  functions;  alanine 
amino-transferase  (ALT)  and  aspartate 
amino-transferase  (AST)  were  determined 
by automatic biochemical analytic apparatus 
using  a  spectrophotometer  (APPLIED  
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BIOSYSTEMS  BTS  310,  Biosystems  of 
New  England,  Inc.  (Waltham, 
Massachusetts,  USA))  at  the  Libyan 
National  Center  for  Infectious  Disease 
Prevention  and  Control,  when  the  patients 
had empty stomachs. Liver function of the 
patients  was  examined  repeatedly  every  4 
weeks till 6 months after therapy. Test tubes 
without anti-coagulant agent used and filled 
every time with 10 ml of blood. 
3. Monitoring hepatic adaptation: 
It  was  detected  by  automatic 
biochemical  analytic  apparatus  using  a 
spectrophotometer  APPLIED 
BIOSYSTEMS  BTS  310,  Biosystems  of 
New  England,  Inc.  (Waltham, 
Massachusetts,  USA))  at  the  Libyan 
National  Center  for  Infectious  Disease 
Prevention and Control. The same previous 
test  tube  sample  was  used  for  this 
detection. 
Statistical Analysis: 
Data  was  analyzed  by  using 
statistics package for social sciences (SPSS 
Statistics  17.0.1)  computer  software 
package  for  statistical  analysis  (IBM 
Corporation,  IBM  Software  Group's 
Business Analytics Portfolio (USA). Results 
were  expressed  as  mean  ±  standard 
deviation  (SD).  Statistical  test  used  was 
student's unpaired t-test, P value       < 0.05 
was considered statistically significant. 
 
RESULTS 
1. Clinical monitoring: Characteristics of 
different  patients  (questionnaire 
analysis): 
Considering  the  seventy  five  TB 
inpatients,  analysis  of  the  questionnaire 
replies (table 2) revealed that age group 30-
39  years  is  more  affected  by  tuberculosis 
more than other age groups; single patients 
are more affected by tuberculosis more than 
married  patients  (70.7%  vs.  29.3%);  the 
smokers  are  more  susceptible  to  TB 
infection  than  non-smokers  (69.3%  vs. 
30.7%);  highly  educated  patients  are  less 
affected (2.6%) when compared to medium- 
and  low-leveled  educated  ones  (78.6%). 
Jobless people were with higher exposure to 
pulmonary  tuberculosis  (58.6%)  than 
employees  (41.4%).  Within  the  examined 
group  of  patients,  many  patients  were 
infected  with  other  disease  conditions  as 
HIV (32%), HBV (3%), and HCV (27%). 
Six  months  after  anti-TB  therapy, 
all  the  inpatients  suffered  from  different 
symptoms,  including  fatigue,  decreased 
appetite, dizziness, nausea … etc. 
 
2. Laboratory monitoring: 
2.1.  Determination  of  hematological 
parameters: 
As  shown  in  table  (3),  the  anti-
tuberculosis  therapy  caused  a  gradual 
significant decrease in the number of WBCs 
count from the beginning of treatment  until 
the end of course (control samples = 9.32 ± 
0.88 x10
3, after one  month = 7.69 ± 0.35 
x10
3,  and  after  six  months  =  5.71  ±  0.55 
x10
3,  n  =  75;  P  <  0.05),  with  percentage 
range of -17.5% to -38.7%, respectively. 
Also,  RBCs  count  showed  a 
significant  decrease  after  one  month  of 
treatment  (5.89  ±  0.36  x10
6    in  control 
samples  vs.  3.66  ±  0.48  x10
6  after  one 
month,  P  <0.05),  with  percentage  of  -
32.1%. However, by the end of the course, 
there was a significant recovery in number 
of RBCs in the end of the course compared 
after one of treatment (4.70±0.35x10
6, when 
compared with the value 3.66 ± 0.48 x10
6 
that was recorded after one months; n = 75; 
P  <0.05)  with  a  recovery  percentage  of 
+22.1%.  
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Table (2): The sociodemographic and clinical characteristics among 75 TB infection inpatients. 
 
Variables 
TB patients (n=75) 
No.  % 
Age group (years): 
    11-19 
    20-29 
    30-39 
    40-49 
    50-59 
    ≥ 60   
 
3 
11 
38 
17 
5 
1 
 
4.0 
14.7 
50.7 
22.6 
6.6 
1.4 
Marital status: 
    Single 
    Married 
 
53 
22 
 
70.7 
29.3 
Educational level: 
    High 
    Medium/low 
 
16 
59 
 
21.4 
78.6 
Job: 
    Have no job 
    Have a job 
 
44 
31 
 
58.6 
41.4 
Smoking status: 
    Yes 
    No 
 
52 
23 
 
69.3 
30.7 
Associated infections: 
    HIV 
    HBV 
    HCV 
 
24 
2 
20 
 
32 
2.7 
26.7 
 
Platelets count exhibited a significant decrease from the beginning of treatment until the 
end of course (in control samples = 429.6 ± 11.9 x10
3, after one month = 330.61 ± 32.69   x10
3, 
after six months = 277.27 ± 15.39 x 10
3; n = 75; P < 0.05) with percentages of -23% and -33%, 
respectively.  
Hemoglobin level exhibited a significant decrease after one month of treatment (14.52 ± 
0.45  g/dl  in  control  samples  vs.  9.74  ±  1.22  g/dl  after  one  month;  n=75;  P  <  0.05)  with 
percentage of -35.5%. However within the course of treatment there was a spontaneous recovery 
in hemoglobin level that was significant after 6 months of treatment (12.19±0.15g/dl compared 
to 9.74 ± 1.22 g/dl that was recorded after one month; n = 75; P < 0.05) and this increase was 
with a percentage of +20.1%.  
 
2.2. Effect of anti-tuberculous drugs on liver function: 
As shown in table (4), ALT level was increased after one month of treatment (36.25 ± 
1.39 U/L in control samples vs. 64.6 ± 3.55 U/L after one month of therapy; n = 75; P < 0.05) 
with  an  increase  percentage  of  +43.9%.  However,  there  was  a  significant  gradual  recovery 
towards the normal value starting from the 2
nd month until the end of course (39.28 ± 1.33 U/L 
after six months, compared to 64.6 ± 3.55 U/L, the value that was recorded after one month; n = 
75; P < 0.05) with a recovery percentage of -39.2%. 
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2.3. Hepatic adaptation: 
As shown in table (4), AST had been increased after one month of treatment (30.31 ± 
1.53 U/L in control samples vs. 47.57 ± 2.98 U/L after one month of anti-TB therapy; n = 75, P 
<  0.05)  with  an  increase  percentage  of  +36.3%.  However,  parallel  to  ALT,  there  was  a 
significant gradual recovery expressed as gradual decrease starting from the 2
nd month until the 
end of course (35.03 ± 0.55 U/L after six month,  compared  to  47.57 ± 2.98 U/L, the value 
that was recorded after one month; n = 75, P < 0.05) with a percentage recovery of -25.8%. 
Similarly, ALP showed an initial increase after one month of treatment (156.17 ± 21.35 
U/L in control samples vs. 281.83 ± 45.8 U/L after one month of anti-TB therapy, n = 75, P < 
0.05) with a percentage of +44.6%. That result was followed by a gradual recovery starting from 
the second month till the end of the course at 6 months (256.67 ± 34.93 U/L after six month, 
compared to 281.83 ± 45.8 U/L, the value that was recorded after one month of therapy; n = 75; 
P <0 .05) with a recovery percentage of -8.9%. 
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DISCUSSION 
The wide prevalence of tuberculosis 
throughout  the  world  makes  it  social  and 
economical  burden  especially  for 
developing  countries  and  the  use  of  anti-
tuberculous drugs is an optimistic approach 
for  this  problem.  However  certain 
reservations associated with its use need to 
be  properly  evaluated  especially  anti-
tuberculosis  treatment-induced  liver  injury 
and the predisposing factors that add to this 
hepatotoxicity (10). 
Our survey shows that tuberculosis 
in Libya can be related to people with low 
income,  bad  habits  and  low  educational 
level, however, some communities provide 
a  better  environment  for  disease 
transmission  than  others.  Previous  surveys 
have  documented  great  disparities  in  rates 
of tuberculosis among neighborhoods (11). 
These  differences  depended,  in  part,  on 
community-level,  ecological  risk  factors 
that  facilitate  transmission-poverty, 
crowding, and other markers of deprivation 
have  long  been  associated  with  increased 
rates of tuberculosis (12, 13). In addition to 
ensuring  treatment  efficiency,  countries 
health  departments  collect  case-specific 
demographic  information  (e.g.,  age,  race, 
foreign-born status) and disease information 
(e.g., site of infection, drug resistance) (14). 
Some  other  studies  have  supported  our 
finding  and  the  role  of  ecological  risk  
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factors, such as low income, lack of social 
capital,  and  overcrowding,  in  tuberculosis 
disease (15, 11, 16, 17). Although  genetic 
differences  have  been  linked  to  increased 
mycobacterial  susceptibility  (18,  19),  our 
study has considered the nationality of the 
patients  under  investigation  whether  they 
are Libyans or non-Libyans; we found that 
most of the patients (94.7%) were Libyans; 
and this may be explained on the basis of 
most  of  non-Libyan  patients  are  not 
recorded, and all foreigners may go to other 
centers  because  of  cost  concern  or  may 
leave the country. Our results was explained 
within  the  context  of  recent  research  on 
“social  capital”  as  a  major  factor  for 
tuberculosis  in  Tripoli  area  as  shown  that 
70.7%  of  patients  were  single,  for  our 
knowledge  always  single  people  cannot 
manage their food or habit culture. 
Major infectious cause of mortality 
in  India  and  many  other  developing 
countries  include  lower  respiratory  tract 
infections, HIV/AIDS, perinatal conditions, 
diarrhoeal  diseases,  tuberculosis,  and 
malaria  (20);  and  all  these  kinds  of 
infectious  diseases  are  related  to  the  low 
level  of  education  and  poverty.  This 
statement  agrees  with  our  study,  where, 
78.6% of monitored patients were found to 
have  low  or  medium  degree  of  education 
and 58.6% were jobless and both of these 
concerns were strongly related to poverty. 
Smoking  and  tobacco  uses  are 
usually  related  in  young  individuals  to 
infections  such  as  lower  respiratory  tract 
infections  and  tuberculosis  and  in  middle 
aged  and  the  elderly  to  cardiovascular 
diseases, cancer, and chronic lung diseases 
(21,  20,  22).  It  is  well  known  in  the 
developed  countries  that  smoking  use  is 
most  prevalent  among  the  least  privileged 
groups  (23,  24).  These  groups  are  the 
unhealthiest  and  face  the  largest  health  in 
equities in terms of preventive, curative and 
rehabilitative  therapies  (25).  As  shown  in 
our survey, we have found that most of our 
TB  patients  are  smokers  (69.3%);  this 
finding  is  consistent  with  other  reports; 
for  example,  tobacco  smoking  was 
associated with a two-fold increased risk of 
active  tuberculosis  in  a  representative 
cohort of Taiwan's population (26). 
Leukopenia may occur in the course 
of  treatment  with  anti-tuberculosis  drugs, 
but  it  is  not  necessary  to  stop  the 
chemotherapy immediately because of this 
fact,  as  the  WBCs  count  recovers 
spontaneously  or  remains  under  stable 
leukopenic  state  during  the  course  of 
chemotherapy  in  most  cases.  However, 
when  leukopenia  appears,  the  peripheral 
blood  counts  must  be  checked  cautiously, 
and the chemotherapy should be stopped if 
the  WBCs  count  progressively  decreases. 
The patients who showed leucopenia due to 
anti-tuberculosis  drugs  may  have  had 
weaker  natural  and  acquired  cell-mediated 
immunologic  response  to  tuberculosis 
infection, and more vulnerable bone marrow 
cells  and  hepatic  cells  to  anti-tuberculosis 
drugs  than  the  control.  Our  result  showed 
leucopenia about -39.83% starting from the 
beginning of treatment figure. This finding 
is  in  agreement  with  Nagayama  et  al. 
(2004)  (27),  who  recorded  leucopenia  due 
to anti-tuberculous chemotherapy, including 
rifampicin and isoniazid. 
Since  RBCs  can  behave  as 
bioreactors  that  are  able  to  convert  pro 
drugs to membrane-releasable active drugs, 
new  compounds  (AZTpEMB, 
AZTpEMBpAZT,  and  AZTp2EMB) 
comprising  both  anti  retro  viral  and  anti 
microbial  drugs  were  designed  and 
synthesized.  Among  these,  only 
AZTp2EMB was hydrolyzed by erythrocyte 
enzymes and could be  encapsulated  inside 
RBCs (28). Our data expressed that RBCs 
count decreased significantly (-32.1%) after 
one  month of anti-TB treatment; however, 
from 2
nd month, it started to recover. This 
may  be  explained  on  the  basis  of  that 
initially  RBCs  undergo  deformation  to 
protect itself from drug toxicity.  
On  the  other  hand,  some  other 
studies  indicated  that  none  of  the  anti-
tuberculosis  drugs  is  without  adverse 
reactions  but  only  rarely  are  the  adverse 
reactions  lives  threatening. 
Thrombocytopenia  (TCP)  is  a  well-known 
complication  following  the  administration 
of  certain  drugs  and  is  characterized  by 
rapid  lowering  of  the  platelet  count 
whenever the offending drug is taken by the 
sensitized  individual.  Rifampicin-induced 
TCP  is  a  rarely  reported  adverse  reaction 
(29). 
To  test  development  of 
thrombocytopenia in  inpatients under  anti- 
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TB therapy, platelet count was included in 
the study. Although there was a decrease in 
platelet  count  after  treatment  as  compared 
to pre treatment, it was within the  normal 
range. This decrease in platelet count  may 
be due to Rifampicin whose one of the side 
effects  is  thrombocytopenia.  The  result  of 
the present study was in agreement with the 
study of Nagayama et al. (2004) (27) that 
was carried out in Japan. Besides, another 
study by Handin (1991) (30) indicated that 
many  drugs  had  effect  on  platelets  in  the 
form  of  reducing  their  number;  however, 
upon discontinuation of the suspected drug, 
there will be regain of the platelets number. 
TCP  was  also  recorded  as  an  adverse 
reaction  associated  with  intermittent 
rifampicin regimen by Toman (1989) (31). 
During  using  anti-tuberculosis  drugs,  if 
purpura  occurred,  rifampicin  should  be 
stopped  immediately  and  should  not  be 
given again even in small doses (32). Those 
previous  data  are  in  agreement  with  these 
stated in the present study that taking anti-
tuberculosis  drugs  had  a  significant 
decreasing effect on the platelets number at 
a percentage of -35.5%. 
Three  fourths  of  the  monitored 
patients  suffered  from  low  hemoglobin 
level so that they may fall in the category 
of  moderate  to  severe  anemia.  Nutritional 
status of our patients was very poor and 61 
patients (91%)  of  them  were below 18.5 
kg/m
2  BMI;  and  27%  of  the  patients 
showed the hypoalbuminemia and this may 
be  one  of  the  risk  factors  of  anti-TB 
therapy-induced  hepatotoxicity  (33).  A 
group  of  researchers  concluded  that 
improvement  of  hematological  status  was 
dependent only on the improvement of the 
disease  process  as  Das  et  al.  (2003)  (34). 
Although a few reports referred to the effect 
of anti-TB therapy on the hemoglobin level, 
yet, our study recorded clearly that the used 
drugs  had  a  lowering  effect  on  the 
hemoglobin  level  only  in  first  month  in 
treatment at a percentage of -33%. 
The possible explanation of anti-TB 
therapy-induced  hepatotoxicity  in 
malnutrition is the depletion of glutathione 
stores  that  makes  one  vulnerable  to 
oxidative  injuries.  Our  study  depicts  the 
same  result  as  a  study  conducted  at  India 
showing  three  times  higher  incidence  of 
anti-TB  therapy-induced  hepatotoxicity  in 
malnourished  patients  (35).  For  our 
knowledge  a  combination  of  drugs  will 
develop  side  effects  on  the  human  body 
organs, and the  most related  organ  is  the 
liver.  Anti-tuberculosis  medication 
frequently  causes  disturbance  to  liver 
function tests and  may  cause serious liver 
function  dysfunction  (36).  Enzymes  for 
drug metabolism in hepatocyte microcosms 
may  have  a  congenital  defect, 
malformation, low activity, or be inhibited 
by drugs, so drug metabolites are very toxic 
to  hepatocytes.  Another  reason  is  th e 
hypersensitivity to drugs. The drugs may act 
as  haptens  causing  allergic  reaction  by 
immune  mechanism  leading  to  the  single 
ALT  increase  in  clinical  situation. 
Commonly  used  anti-TB  drugs,  such  as 
isoniazid,  rifampicin,  pyrazinamide, 
ethambutol,  etc.,  are  all  hepatotoxic, 
especially  when  rifampicin  and 
pyrazinamide are used in combination (37). 
Isoniazid  causes  hepatic  damage  either  by 
the  toxicity  of  or  hypersensitivity  induced 
by  its  metabolite-acehydrazide. 
Rifampicinmay  accelerate  the  metabolism 
of  isoniazid  as  astrong  enzyme  inducer 
resulting  in  the  increase  of  acehydrazide. 
Acehydrazide  combines  with  bio  macro-
molecules in liver leading to hepatocellular 
damage usually seen in aged patients with 
excessive  drinking,  malnutrition  or  a  liver 
ailment.  Pyrazinamide’s  hepatotoxicity  is 
dose-dependent and the general dose rarely 
causes  hepatic  damage.  Isoniazid  and 
rifampicin  are  the  first  line  anti-TB 
medicines  because  of  their  strong 
bactericidal  effects.  However,  rifabutin, 
amikacin,  ofloxacin,  levofloxacin,  etc., 
treatment plan have not been reported with 
obvious hepatotoxicity (38, 39). It had been 
reported  that  rifampin  appears  to  enhance 
metabolic  hepatocellular  idiosyncratic 
reaction  in  patients  receiving  isoniazid, 
perhaps by promoting the formation of toxic 
isoniazid  metabolites  (40).  The  use  of 
multidrug  regimens  for  the  treatment  of 
tuberculosis  based  on  the  combination  of 
isoniazid,  rifampin,  ethambutol,  and/or 
pyrazinamide  has  proven  to  be  a  highly 
effective  therapy  (41).  However,  its  
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effectiveness  is  offset  by  the  increased 
incidence  of  drug-induced  hepatotoxicity. 
The  development  of  drug-induced 
hepatotoxicity is often of great concern, as 
it  often  necessitates  the  cessation  or 
modification  of  treatment  (42).  The 
occurrence  of  liver  injury  during  anti-
tuberculosis treatment varies, and appears to 
be much higher in developing countries (up 
to 39%) than in developed countries (3-4%) 
(43); despite of the use of similar regimens. 
The  reasons  for  this  higher  incidence  of 
drug-induced  hepatotoxicity  in  developing 
countries  remain  unclear.  It  has  been 
suggested  that  this  may  be  attributable  to 
viral  hepatitis,  which  is  particularly 
prevalent in the developing world (44). 
In our study the patients developed 
anti-TB-induced  hepatotoxicities  indicated 
by  increasing  of all  of the three  enzymes, 
43.9% for ALT, 36.6% for AST and 44.6% 
for  ALK  that  almost  over  lap  the  study 
conducted in Japan by Ohno et al. (2000) 
(45). 
The  combination  of  multi  drug 
therapy for tuberculosis has been associated 
with increased risk of hepatotoxicity when 
compared with INH mono therapy used for 
TB  prophylaxis  (46).  The  reported 
incidence of anti-TB-induced hepatotoxicity 
is different in various countries though not 
fully  understood  but  could  be  due  to  the 
characteristics  and  the  risk  factors  of  the 
population studied, the different diagnostic 
criteria  used  to  define  hepatotoxicity, 
different  geographical  areas,  tests  carried 
out  during  follow  ups  and  the  type  of 
monitoring (47). Parallel studies conducted 
in  Nepal  and  Hong  Kong  resulted  in 
increase  in  hepatic  biomarkers  with 
percentages of 8% and 13%, respectively. 
Four prospective Indian studies documented 
the  risk  of  anti-TB-induced  hepatotoxicity 
as11.5%  compared  with  4.3%  in  fourteen 
published  studies  from  west  (48). 
Hepatotoxicity  occurs  generally  within 
weeks  to  months  rather  than  the  days  to 
weeks  of  onset  seen  with  hypersensitivity 
reactions (49). In addition, only one study 
(50) has examined the risk of drug-induced 
hepatotoxicity in standard short-course anti-
TB treatment in patients  with clinical TB. 
Studies in the1950s suggested that elevated 
glutamate pyruvate transaminases occurred 
in 20%, and overt hepatitis in 8%, of those 
treated with pyrazinamide, which has some 
structural  resemblance  to  isoniazid  (1). 
Experience  with  lower  dose  regimens,  in 
combination with other agents, suggests that 
there is only a small risk of hepatocellular 
injury  (51),  though  cases  of  fatal  hepatic 
necrosis  have  been  described  (52). 
Younossian  et  al.  (2005)  (53)  concluded 
that combing pyrazinamide and ethambutol 
for  latent  tuberculosis  infection  may  be 
associated  with  a  high  risk  of  hepatic 
toxicity,  and  warrants  close  monitoring. 
There  is  clearly  a  need  for  alternative 
preventive treatments for contacts exposed 
to  multidrug-resistant  tuberculosis. 
Thompson  et  al.  (1995)  (36)  suggested  a 
protocol  for  using  liver  function  tests  to 
monitor  for  liver  damage,  and  give 
recommendations  on  what  action  to  take 
when  these  become  abnormal  and  same 
suggestion  been  supported  by  other  group 
as  Parthasarathy  et  al.  (1986)  (42).  In  a 
study in Hong Kong, 1,386 Chinese patients 
with  sputum  smear-positive  pulmonary 
tuberculosis  were  under  treatment  for  6 
month  with  combinations  of  anti-
tuberculosis drugs recorded non-significant 
differences between the regimens with and 
without  streptomycin  (54).  Even  the 
recovery of the liver is a normal mechanism 
as  the  body  rebuilds  its  own  cells,  which 
agree  with  our  results  for  all  three  liver 
function  enzymes.  There  are  many  risk 
factors of hepatic damage during the course 
of  anti-TB  treatment,  such  as  the  type  of 
tuberculosis,  recurred  tuberculosis,  HBV 
infection,  alcohol  drinking,  age,  nutrition 
status,  heredity,  individual  difference  and 
immune status, etc. Scholars outside China 
reported that most  of  hepatocytes  in HBV 
carriers  without  clinical  symptoms  had 
changes  in  histology  and  spot  necrosis  in 
some hepatocytes. One researcher took liver 
biopsies  from  25  pulmonary  tuberculosis 
patients  with  HBV  infection  during  the 
course of anti-TB treatment and discovered 
that all the patients  with  liver  dysfunction 
suffered  from  viral  hepatitis,  even  liver 
cirrhosis.  Hepatic  damage  of  the  patients 
with  pulmonary  tuberculosis  during  the 
course of anti-TB treatment was related to 
HBV infection and pre-existing pathologic 
changes  in  liver.  Anti-TB  medicines  only 
aggravated pre-existing hepatic damage (55, 
56). So, HBV infection or pre-existing liver  
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ailment  might  be  an  important  risk  factor 
(57, 58). Hepatotoxicity caused by anti-TB 
medicines was liable to happen in the first 
2-3 months of aggressive anti-TB treatment. 
Hepatic  damage  of  the  patients  with 
positive HBV was caused by viral damage 
over lapped by medicine damage (59). The 
prevalence of TB was reported to be higher 
among  hepatitis- C  virus-infected  (HCV) 
patients than among those without infection 
(60).  However,  the  relationship  between 
HCV  infection  and  the  development  of 
drug-induced  hepatotoxicity  during 
treatment  for  TB  is  not  well  defined  in 
literature  (50,  61).  Percentage  of  patients 
which  are  infected  with  other  kind  of 
disease can be seen in HIV. 
In  conclusion,  we  can  state  that 
manifestations of side effects related to anti-
tuberculosis treatment with our regimen in 
the population of the tuberculosis inpatient 
clinic  of  the  Abo-Seta  hospital  are 
apparent. However, in the great majority of 
cases,  it  was  not  necessary  to  modify  the 
treatment  regimen  due  to  adverse  effects. 
These  results  show  the  importance  of  the 
early  recognition  of  these  effects  and  the 
early initiation of the appropriate approach. 
It  is  fundamental  to  follow  the 
recommendation  of  the  National  Health 
Foundation  Guide  to  Epidemiological 
Surveillance  of  Tuberculosis  (62)  that 
clinical follow-up evaluations of patients be 
carried out by health professionals at least 
once  a  month  and  includes  an  interview 
regarding the possible signs and symptoms 
related to side effects. 
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